ZURA's Quality Score fell 3 points on Mon, Nov 9, to -7.
Follow ZURA's trial news. Pro members can get an alert when Zura Bio files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 27% in 3 months while the S&P 500 fell 5%.
−3News
| Holding it back | 34.5% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
After its last 4 reports it closed +0.3% on average, higher 1 of 4 times.
$205M in cash
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ZURA is #249 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 249 |
Expected to report Thu Mar 18, before the open (in 129 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.20 a share, from $0.21.
“The increase was primarily driven by t h e continued execution of Zura’s Phase 2 tibulizumab clinical programs as well as start-up activities for NEXUS-PMR.”
ZURA gives its mix in its presentation's charts, not in a table we read.
No outlook figures read from this release.
“Zura expects that its existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028.”
From its results filing (SEC filing · Oct 27)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 27, 2026 | +0.3% | +19.9% | +10.7% |
| Aug 11, 2026 | +1.2% | -1.2% | +0.9% |
| May 7, 2026 | +0.2% | -7.2% | -1.8% |
RSI 50.0, MACD above signal, below both averages. Not scored.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
ZURA scores -7 today, which Breakaway calls Poor. It is #249 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 27% in 3 months while the S&P 500 fell 5%. Shares: 34.5% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ZURA scores -7 today, which Breakaway calls Poor (below zero). That is #249 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ZURA's -7.
Expected to report Thu Mar 18, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ZURA closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.